Permanent prostate brachytherapy: Is supplemental external-beam radiation therapy necessary?

ONCOLOGY

Volumn 20, Issue 5, 2006, Pages 514-522

  Merrick, Gregory S ^a,d   Wallner, Kent E ^b   Butler, Wayne M ^a   Blasko, John C ^c  

^a WHEELING JESUIT UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SWEDISH MEDICAL CENTER   (United States)

^d WHEELING HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LONG TERM CARE; PELVIS LYMPH NODE; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEMINAL VESICLE; TREATMENT OUTCOME; URINARY DYSFUNCTION; ADJUVANT THERAPY; BRACHYTHERAPY; DISEASE FREE SURVIVAL; ECONOMICS; MALE; MEGAVOLTAGE RADIOTHERAPY; METHODOLOGY; PATHOLOGY; PRACTICE GUIDELINE; PROSTATE TUMOR; RADIATION DOSE; RADIATION EXPOSURE; RISK;

BRACHYTHERAPY; DISEASE-FREE SURVIVAL; HUMANS; MALE; PRACTICE GUIDELINES; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, HIGH-ENERGY; RANDOMIZED CONTROLLED TRIALS; RISK; SEMINAL VESICLES;

EID: 33750105132     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Merrick GS, Wallner KE, Butler WM: Permanent interstitial brachytherapy in the management of carcinoma of the prostate gland. J Urol 69:1643-1652, 2003.
2. Merrick GS, Butler WM, Wallner KE, et al: Impact of supplemental external-beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61:32-43, 2005.
3. Merrick GS, Wallner KE, Butler WM: Minimizing prostate brachytherapy-related morbidity. Urology 62:786-792, 2003.
4. Blasko JC, Grimm PD, Sylvester JE, et al: Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 46:839-850, 2000.
5. Grimm PD, Blasko JC, Sylvester JE, et al: 10-year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapy. Int J Radiat Oncol Biol Phys 251:31-40, 2001.
6. Critz FA: A standard definition of disease freedom is needed for prostate cancer: Undetectable prostate specific antigen compared with the American Society for Therapeutic Radiology and Oncology consensus definition. J Urol 167:1310-1313, 2002.
7. Dattoli M, Wallner K, True L, et al: Long-term outcomes after treatment with external-beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma. Cancer 97:979-983, 2003.
8. Merrick GS, Butler WM, Dorsey AT, et al: The effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation. Tech Urol 7:233-240, 2001.
9. Merrick GS, Butler WM, Wallner KE, et al: Extracapsular radiation dose distribution following permanent prostate brachytherapy. Am J Clin Oncol 26:E178-E189, 2003.
10. Choi S, Wallner K, Merrick G, et al. Treatment margins predict biochemical outcome after prostate brachytherapy. Cancer J Sci Am 10:175-180, 2004.
11. Nag S, Beyer D, Friedland J, et al: American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44:789-799, 1999.
12. Potters L, Torre T, Ashley R, et al: Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol 18:1187-1192, 2000.
13. Lee L, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 52:444-452, 2002.
14. Partin AW, Mangold LA, Lamm DA, et al: Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millenium. Urology 58:843-848, 2001.
15. Davis BJ, Pisansky TM, Wilson TM, et al: The radial distance of extraprostatic extension of prostate carcinoma: Implications for prostate brachytherapy. Cancer 85:2630-2637, 1999.
16. Sohayda C, Kupelian PA, Levin HS, et al: Extent of extracapsular extension in localized prostate cancer. Urology 55:382-386, 2000.
17. Teh BS, Bastasch MD, Mai W-Y, et al: Predictors of extracapsular extension and its radial distance in prostate cancer: Implications for prostate IMRT, brachytherapy and surgery. Cancer J 9:454-460, 2003.
18. Merrick GS, Butler WM, Dorsey AT, et al: Seed fixity in the prostate/periprostatic region following brachytherapy. Int J Radiat Oncol Biol Phys 46:215-220, 2000.
19. Merrick GS, Butler WM, Wallner KE, et al: Prognostic significance of perineural invasion on biochemical progression-free survival following prostate brachytherapy. Urology 66:1048-1053, 2005.
20. Gancarczyk KJ, Wu H, McLeod DG, et al: Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: The Center for Prostate Disease Research nomograms. Urology 61:589-595, 2003.
21. Merrick GS, Butler WM, Wallner KE, et al: Prognostic significance of percent positive biopsies in clinically organ-confined prostate cancer treated with permanent prostate brachytherapy with or without supplemental external-beam radiation. Cancer J 10:54-60, 2004.
22. Kollmeier MA, Stock RG, Stone NN: Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 7:645-653, 2003.
23. Merrick GS, Butler WM, Dorsey AT, et al: The dependence of prostate post-implant dosimetric quality of CT volume determination. Int J Radiat Oncol Biol Phys 44:1111-1117, 1999.
24. Merrick GS, Butler WM: Modified uniform seed loading for prostate brachytherapy: Rationale, design, and evaluation. Tech Urol 6:78-684, 2000.
25. Reed DR, Wallner KE, Narayanan S, et al: Intraoperative fluoroscopic dose assessment in prostate brachytherapy patients. Int J Radiat Oncol Biol Phys 63:301-307, 2005.
26. Kestin LL, Goldstein NS, Vicini FA, et al: Treatment of prostate cancer with radiotherapy: Should the entire seminal vesicles be included in the clinical target volume? Int J Radiat Oncol Biol Phys 54:686-697, 2002.
27. Stock RG, Lo Y-C, Gaildon M, et al: Does prostate brachytherapy treat the seminal vesicles? A dose-volume histogram analysis of seminal vesicles in patients undergoing combined Pd-103 prostate implantation and external-beam irradiation. Int J Radiat Oncol Biol Phys 45:385-389, 1999.
28. Roach III M, DeSilvio C, Lawton V, et al: Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21:1904-1911, 2003.
29. Merrick GS, Butler WM, Wallner KE, et al: Variability of prostate brachytherapy preimplant dosimetry: A multi-institutional analysis. Brachytherapy 4:241-251, 2005.
30. Roberson PL, Narayana V, McShan DL, et al: Source placement error for permanent implant of the prostate. Med Phys 24:251-257, 1997.
31. Dawson JE, Wu T, Roy T, et al: Dose effects of seed placement deviations from preplanned positions in ultrasound guided prostate implants. Radiother Oncol 32:268-270, 1994.
32. Davis BJ, Haddock MG, Wilson TM, et al: Treatment of extraprostatic cancer in clinically organ-confined prostate cancer by permanent interstitial brachytherapy: Is extraprostatic seed placement necessary? Tech Urol 6:70-77, 2000.
33. Prostate, in American Joint Committee on Cancer: AJCC Cancer Staging Manual, 6th ed, pp 309-316. New York, Springer, 2002.
34. Sharkey J, Cantor A, Solc Z, et al: 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: A 12-year experience from a single group practice. Brachytherapy 4:34-44, 2005.
35. Potters L, Morgenstern C, Calugaru E, et al: 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173:1562-1566, 2005.
36. Ragde H, Blasko JC, Grimm PD, et al: Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer 80:442-453, 1997.
37. Ragde H, Elgamal AA, Snow PB, et al: Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external-beam irradiation in the treatment of patients with clinically localized, low to high Gleason's grade, prostate carcinoma. Cancer 83:989-1001, 1998.
38. Blasko JC, Grimm PD, Sylvester JE, et al: The role of external-beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 57:273-278, 2000.
39. Merrick GS, Butler WM, Wallner KE, et al: The impact of primary Gleason grade on biochemical outcome following brachytherapy for Gleason score 7 prostate cancer. Cancer J 11:234-240, 2005.
40. Merrick GS, Butler WM, Galbreath RW, et al: Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external-beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer? BJU Int 91:23-29, 2003.
41. Brachman DG, Thomas T, Hilbe J, et al: Failure-free survival following brachytherapy alone or external-beam irradiation alone for T1-2 prostate tumors in 2222 patients: Results from a single practice. Int J Radiat Oncol Biol Phys 48:111-117, 2000.
42. D'Amico AV, Whittington R, Malkowicz B, et al: Biochemical outcome after radical prostatectomy, external-beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998.
43. Kwok Y, DiBiase SJ, Amin PP, et al: Risk group stratification in patients undergoing permanent 125I prostate brachytherapy as monotherapy. Int J Radiat Oncol Biol Phys 53:588-594, 2002.
44. Merrick GS, Butler WM, Wallner KE, et al: Long-term urinary quality of life following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 56:454-61, 2003.
45. Merrick GS, Butler WM, Wallner KE, et al: Risk factors for the development of prostate brachytherapy-related urethral strictures. J Urol 175:1376-1381, 2006.
46. Merrick GS, Butler WM, Wallner KE, et al: Late rectal function following prostate brachytherapy. Int J Radiat Oncol Biol Phys 1:42-48, 2003.
47. Merrick GS, Butler WM, Wallner KE, et al: Rectal function following brachytherapy: Results of two prospective randomized trials. Int J Radiat Oncol Biol Phys 57(suppl 2):S230, 2003.
48. Merrick GS, Butler WM, Wallner KE, et al: The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction. Int J Radiat Oncol Biol Phys 54:1055-1062, 2002.
49. Merrick GS, Butler WM, Wallner KE, et al: Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 62:437-447, 2005.
50. Merrick GS, Butler WM, Lief JH, et al: Efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dysfunction. Urology 53:1112-1116, 1999.
51. Wallner K, Merrick G, True L, et al: 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: Early biochemical outcomes from a prospective randomized multi-center trial. Radiother Oncol 75:307-310, 2005.